Argent BioPharma Expands Pipeline with Promising Drug CimetrA

PERTH, Australia, March 16, 2025 /PRNewswire/ -- ArgentBioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company addressing unmet medical needs by developing innovative treatments for central nervous system and immune-related disorders through neuro-immune modulation and advanced nano-medicine technology, is pleased to announce positive Phase IIb clinical trial results for CimetrA, a novel anti-inflammatory treatment. The study confirmed CimetrA's strong safety profile and demonstrated faster recovery times in COVID-19 patients.

Key Findings:

• No drug-related adverse events, reinforcing CimetrA's safety.
• Faster clinical improvementversus placebo, measured by the WHO Ordinal Scale.
• Reduced inflammation, with significant modulation of key inflammatory markers (IL-6, IL-1, TNF-, and more).
• Improved quality of life trends observed in CimetrA-treated patients.

CEO Roby Zomerstated:
"These promising results highlight CimetrA's potential as a breakthrough treatment for inflammatory diseases beyond COVID-19. We are excited about its future clinical development."

With these findings, Argent BioPharma continues to advance innovative therapies. One such therapy, CannEpil, is an oral mucosal solution with a high-CBD, low-THC formulation. It is designed to reduce seizure frequency and severity while minimizing psychoactive effects. After years of clinical development, CannEpilis making waves in the UK as part of a movement to transform severe epilepsy treatment. This further reinforces Argent BioPharma's commitment to addressing global health challenges.

For further information, please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
[emailprotected]

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
[emailprotected]

SOURCE Argent BioPharma Ltd.